CD5+DLBCL
Conditions
Interventions
experimental group:IRM-CHOP regimen
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects must meet all of the following criteria to be enrolled: 1. For newly diagnosed CD5+DLBCL confirmed by pathological tissue (except primary mediastinal large B-cell lymphoma, primary central lymphoma, testicular lymphoma and HIV-related lymphoma), the diagnostic criteria refer to WHO 2016 diagnostic criteria. 2. Age =75 years old with ECOG PS=2 points; 3. Life expectancy is more than 6 months; 4.Ann Arbor stage I-IV; Follow-up is available. The patients knew the characteristics of the disease and voluntarily joined the study protocol for treatment and follow-up.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria are not eligible for inclusion in this study: 1. Patients with abnormal liver and kidney function, specifically serum direct bilirubin, serum indirect bilirubin and/or glutamic-pyruvic transaminase, aspartate transaminase, and serum creatinine > 2 normal values, unless abnormal liver and kidney function is identified as associated with lymphoma; 2. Patients with bone marrow failure, specifically defined as absolute neutrophil count (ANC) 1104 copies /ml) and hepatitis C patients; 6. Lymphoma has been shown to involve the central nervous system; 7. Has been diagnosed with or is undergoing treatment for a malignancy other than lymphoma, except for: ? had received treatment for the purpose of cure, and had no malignancies with known active disease for =5 years prior to enrollment; ? Well-treated basal cell carcinoma of the skin with no signs of disease (except melanoma); ? Well-treated carcinoma in situ of the cervix with no signs of disease. 8. Patients with other hematological diseases (such as hemophilia, myelofibrosis, etc.) are considered not suitable for admission; 9. Complicated with severe infection; 10. Received secondary or higher surgery within 3 weeks prior to treatment; 11. Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study or the evaluation of the study results; 12. Those who were considered unsuitable for inclusion by the researchers; Known allergy to test drug ingredients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate;complete remission rate;part remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;progression-free survival; | — |
Countries
China
Contacts
Public ContactWei Sang
The Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed